RxDoctor Payments Data

Richard Mercer, APRN

Psychiatric/Mental Health · Jacksonville, FLNPI 1306456025

Payments from drug & device makers

$7,124in general payments, 2019–2025

Across 354 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$902
  • Teva Pharmaceuticals USA, Inc.$623
  • Johnson & Johnson$607
  • Otsuka America Pharmaceutical, Inc.$585
  • Axsome Therapeutics, Inc.$508
  • plus $3K from 18 others

What the payments were for

  • Food & beverage$7,124100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,124 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$81,426
Medicare patients
308
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine20$126,893
CaplytaLumateperone Tosylate34$59,624
Abilify MaintenaAripiprazole13$41,793
RexultiBrexpiprazole23$26,513
DayvigoLemborexant13$4,400
Aripiprazole43$3,924
Mirtazapine127$3,615
Quetiapine Fumarate108$3,071
Escitalopram Oxalate224$2,822
Duloxetine Hcl102$2,282
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25$2,163
Divalproex Sodium ErDivalproex Sodium58$2,145
Divalproex Sodium35$1,744
Trazodone Hcl195$1,580
Ramelteon14$1,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$623$126,89320 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$585$68,30736 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,047$59,62434 claims
Almatica Pharma LLCSertraline Hcl$166$81375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →